Celecoxib/tramadol
Combination drug
From Wikipedia, the free encyclopedia
Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]
Trade namesSeglentis
Other namesE-58425
| Combination of | |
|---|---|
| Celecoxib | Nonsteroidal anti-inflammatory drug (NSAID) |
| Tramadol hydrochloride | Opioid agonist |
| Clinical data | |
| Trade names | Seglentis |
| Other names | E-58425 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]
